On February 24, 2026 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported financial results for the full year and fourth quarter of 2025 and provided financial guidance for 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"2025 was an exceptional year for Jazz, representing our 21st consecutive year of top-line growth and underscoring our commitment to operational excellence as we deliver meaningful innovation for patients," said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals. "In the fourth quarter, our disciplined execution resulted in $1.2 billion in revenue, reflecting 10% year-over-year growth and our highest revenue quarter ever. This performance provides us with strong momentum into 2026, as we prepare for the potential launch of zanidatamab in GEA, sustain launch execution for Modeyso and Zepzelca, and reinforce the differentiated profiles of Epidiolex and Xywav as the leading branded treatments for epilepsy and narcolepsy, respectively. In parallel, we continue to advance our pipeline and pursue a corporate development strategy aligned with our rare disease focus that supports durable growth and long-term value creation for patients and shareholders."

"Jazz had a transformative year across our R&D pipeline, led by the HERIZON-GEA-01 data, which we believe firmly positions zanidatamab as the HER2-targeted agent of choice, with the potential to reshape first-line treatment for HER2+ metastatic GEA patients," said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development, and chief medical officer of Jazz Pharmaceuticals. "We expect to build on this progress in 2026, as these results not only highlight zanidatamab’s potential to help patients with GEA, but also de-risk our clinical trials in additional indications, including HER2+ metastatic breast cancer."

Key 2025 Highlights

•Total revenues in 2025 grew to $4.3 billion (+5% year-over-year (YoY)), generating $1.4 billion in cash from operations.
•Research & Development:
◦Practice-changing Phase 3 HERIZON-GEA-01 results support zanidatamab as the HER2-targeted agent of choice in HER2+ 1L gastroesophageal adenocarcinoma (GEA), regardless of PD-L1 status.
◦Multiple registrational trials of zanidatamab are underway, including in metastatic breast cancer (mBC), supporting a broad development program designed to maximize patient impact and long-term shareholder value.

•Commercial:
◦Continued leadership in rare sleep with Xywav net product sales increasing to $1.7 billion (+12% YoY) and total sleep franchise1 revenues exceeding $2 billion in 2025.
◦Epidiolex/Epidyolex generated more than $1 billion in 2025 net product sales (+9% YoY).
◦Completed acquisition of Chimerix Inc., secured FDA approval for and successfully launched Modeyso (dordaviprone) in H3 K27M-mutant diffuse midline glioma, achieving $48 million in sales since launch in August 2025.
◦Received FDA approval and launched Zepzelca, in combination with atezolizumab, for first-line maintenance treatment of extensive-stage small cell lung cancer.
•Company expects 2026 total revenue of between $4.25 and $4.50 billion, with double-digit growth across the combined epilepsy and oncology franchises, and Xywav revenue flat to up mid-single digits.
•Tom Riga was named chief business officer to accelerate corporate development efforts across rare disease.

Business Updates

Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution:
•Xywav net product sales increased 12% to $1.7 billion in 2025 and increased 16% to $465 million in 4Q25 compared to the same periods in 2024.
•Strong new patient growth continued, with approximately 500 net patient adds in 4Q25. There were approximately 16,175 active patients exiting the quarter, comprised of approximately 10,950 narcolepsy patients and approximately 5,225 idiopathic hypersomnia (IH) patients.

Epidiolex/Epidyolex (cannabidiol):
•Epidiolex/Epidyolex achieved blockbuster status in 2025 with net product sales increasing 9% to $1.1 billion in 2025 and increasing 4% to $287 million in 4Q25 compared to the same periods in 2024.

Ziihera (zanidatamab-hrii):
•Ziihera net product sales in biliary tract cancer (BTC) were $25 million in 2025 and $9 million in 4Q25 following product launch in December 2024.
•Expect to complete supplemental biologics license application (sBLA) submission under Real Time Oncology Review (RTOR) in 1Q26 with potential launch in 1L HER2+ GEA in 2H26.
•FDA granted Breakthrough Therapy designation (BTD) for zanidatamab’s development for patients with HER2+ unresectable locally advanced or metastatic GEA.
•Submitted HERIZON-GEA-01 data for potential inclusion in National Comprehensive Cancer Network (NCCN) guidelines.
•EmpowHER-BC-303 trial in mBC patients previously treated with, or intolerant to, trastuzumab deruxtecan on track to complete enrollment in 1H27, with top-line results expected in late 2027 or early 2028.

Modeyso (dordaviprone):
•Following product launch in August 2025, Modeyso net product sales were $48 million in 2025 and $37 million in 4Q25.
•The Company sold its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $200 million (50% to Jazz).

Zepzelca (lurbinectedin):
•Zepzelca net product sales decreased 4% to $307 million in 2025 and increased 15% to $90 million in 4Q25 compared to the same periods in 2024.

Financial Highlights
Three Months Ended
December 31, Year Ended
December 31,
(In thousands, except per share amounts) 2025 2024 2025 2024
Total revenues $ 1,197,926 $ 1,088,173 $ 4,267,586 $ 4,068,950
GAAP net income (loss) $ 203,451 $ 191,115 $ (356,148) $ 560,120
Non-GAAP adjusted net income1
$ 420,888 $ 400,525 $ 521,924 $ 1,351,970
GAAP earnings (loss) per share $ 3.21 $ 3.11 $ (5.84) $ 8.65
Non-GAAP adjusted earnings per share1
$ 6.64 $ 6.51 $ 8.38 $ 20.65

____________________________
1.Commencing with the first quarter of 2025, we are no longer including an adjustment for non-cash interest expense in the Company’s non-GAAP adjusted financial measures and for the purposes of comparability, non-GAAP adjusted financial measures for the 2024 periods have been updated to reflect this change. See "Non-GAAP Financial Measures" below.

Reconciliations of applicable GAAP reported to non-GAAP adjusted information are included at the end of this press release.
Total Revenues
Three Months Ended
December 31, Year Ended
December 31,
(In thousands) 2025 2024 2025 2024
Xywav $ 465,451 $ 400,964 $ 1,656,986 $ 1,473,202
Xyrem 37,781 49,290 146,034 233,816
Epidiolex/Epidyolex 287,122 275,047 1,059,197 972,423
Sativex 1,503 5,173 16,277 18,877
Total Neuroscience 791,857 730,474 2,878,494 2,698,318
Rylaze/Enrylaze 108,160 101,487 402,920 410,846
Zepzelca 90,440 78,328 307,309 320,318
Defitelio/defibrotide 58,872 57,650 199,392 216,565
Vyxeos 34,731 53,247 146,709 162,595
Modeyso 36,541 — 48,043 —
Ziihera 8,538 1,051 24,810 1,051
Total Oncology 337,282 291,763 1,129,183 1,111,375
Other 3,309 2,974 14,172 11,471
Product sales, net 1,132,448 1,025,211 4,021,849 3,821,164
High-sodium oxybate AG royalty revenue 55,696 55,307 211,725 217,575
Other royalty and contract revenues 9,782 7,655 34,012 30,211
Total revenues $ 1,197,926 $ 1,088,173 $ 4,267,586 $ 4,068,950

3

Total revenues increased 5% in 2025 and 10% in 4Q25 compared to the same periods in 2024.
Total neuroscience revenue, including high-sodium oxybate AG royalty revenue, was $3.1 billion in 2025, an increase of 6% compared to $2.9 billion in 2024, and $848 million in 4Q25, an increase of 8% compared to $786 million in 4Q24. The increase in both periods was primarily due to higher Xywav and Epidiolex/Epidyolex net product sales, partially offset by decreased Xyrem net product sales.
Oncology net product sales were $1.1 billion in 2025, an increase of 2% compared to 2024, and $337 million in 4Q25, an increase of 16% compared to $292 million in 4Q24, primarily due to the inclusion of Modeyso and Ziihera net product sales in both periods. The increase in 4Q25 also included higher Zepzelca net product sales, partially offset by decreased Vyxeos net product sales.

Operating Expenses and Income Tax (Benefit) Expense
Three Months Ended
December 31, Year Ended
December 31,
(In thousands, except percentages) 2025 2024 2025 2024
GAAP:
Cost of product sales $ 153,528 $ 128,713 $ 503,296 $ 445,713
Gross margin on product sales, net 86.4% 87.4% 87.5% 88.3%
Selling, general and administrative $ 406,212 $ 369,287 $ 1,809,271 $ 1,385,294
% of total revenues 33.9% 33.9% 42.4% 34.0%
Research and development $ 213,909 $ 240,500 $ 782,736 $ 884,000
% of total revenues 17.9% 22.1% 18.3% 21.7%
Acquired in-process research and development $ — $ — $ 947,862 $ 10,000
Income tax (benefit) expense $ 4,963 $ (57,912) $ (272,443) $ (91,429)
Effective tax rate 2.4% (43.5)% 43.4% (19.4)%

Three Months Ended
December 31, Year Ended
December 31,
(In thousands, except percentages) 2025 2024 2025 2024
Non-GAAP adjusted:
Cost of product sales $ 106,841 $ 86,492 $ 336,016 $ 295,897
Gross margin on product sales, net 90.6% 91.6% 91.6% 92.3%
Selling, general and administrative $ 360,533 $ 323,167 $ 1,603,255 $ 1,226,724
% of total revenues 30.1% 29.7% 37.6% 30.1%
Research and development $ 189,915 $ 220,857 $ 686,645 $ 809,327
% of total revenues 15.9% 20.3% 16.1% 19.9%
Acquired in-process research and development $ — $ — $ 947,862 $ 10,000
Income tax (benefit) expense $ 73,628 $ (435) $ (26,467) $ 127,093
Effective tax rate 14.9% (0.1)% (5.3)% 8.6%

Changes in operating expenses and income tax (benefit) expense in 2025 and 4Q25 over the prior year periods are primarily due to the following:
•Cost of product sales, on a GAAP and non-GAAP adjusted basis, increased in 2025 compared to 2024, primarily due to changes in product mix. Cost of product sales, on a GAAP basis, in 2025 included higher acquisition accounting inventory fair value step up expense compared to 2024. Cost of product sales, on a GAAP and non-GAAP adjusted basis, increased in 4Q25 compared to 4Q24, primarily due to changes in product mix, partially offset by lower inventory provisions.
•Selling, general and administrative (SG&A) expenses, on a GAAP and non-GAAP adjusted basis, increased in 2025 compared to 2024, primarily due to Xyrem antitrust litigation settlements of $234 million, the Avadel litigation settlement of $90 million and higher compensation-related expenses. SG&A expenses, on a GAAP and non-GAAP adjusted basis, increased in 4Q25 compared to 4Q24, primarily due to higher compensation-related expenses.
•Research and development (R&D) expenses, on a GAAP and non-GAAP adjusted basis, decreased in 2025 and 4Q25, compared to the same periods in 2024, primarily due to lower clinical study costs primarily related to zanidatamab as a result of timing of clinical trial activities, JZP385 (essential tremor) following discontinuation of this program, and JZP258 (XYLO/DUET) due to the completion of these trials in the first half of 2025, partially offset by the addition of costs relating to Modeyso and increased personnel costs following the acquisition of Chimerix.
•Acquired in-process research and development (IPR&D) in 2025, on a GAAP and non-GAAP adjusted basis, represents the value allocated to Modeyso in the Chimerix Acquisition of $905 million and the upfront payment made in connection with our global license agreement with Saniona of $43 million.
•Income tax benefit in 2025, on a GAAP and non-GAAP adjusted basis, included a benefit of $213 million on recognition of certain U.S. federal and state deferred tax assets acquired through the Chimerix acquisition. Income tax benefit, on a GAAP and non-GAAP adjusted basis, in 4Q24 was primarily due to patent box benefits recognized.

Cash Flow and Balance Sheet
As of December 31, 2025, cash, cash equivalents and investments were $2.4 billion, and the outstanding principal balance of the Company’s long-term debt was $5.4 billion. In addition, the Company had undrawn borrowing capacity under a revolving credit facility of $885 million. For the year ended December 31, 2025, the Company generated $1.4 billion of cash from operations reflecting strong business performance and continued financial discipline.

2026 Financial Guidance
Jazz Pharmaceutical’s full year 2026 financial guidance is as follows:

(In millions) Guidance
Total Revenues $4,250 – $4,500

(In millions, except percentages) GAAP Non-GAAP
Gross margin % 89% – 90%
90% – 91%1
SG&A expenses $1,424 – $1,497
$1,260 – $1,3201
R&D expenses $811 – $867
$725 – $7751
Effective tax rate 0% – 10%
11.5% – 13.5%1
Weighted-average ordinary shares outstanding2
65 – 66 65 – 66

Conference Call Details
Jazz Pharmaceuticals will host an investor conference call and live audio webcast today at 4:30 p.m. ET (9:30 p.m. GMT) to provide a business and financial update and discuss its 2025 full year and 4Q25 results and 2026 guidance.

(Press release, Jazz Pharmaceuticals, FEB 24, 2026, View Source [SID1234662919])

On February 24, 2026 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, reported fourth quarter and full year 2025 financial results, business achievements and corporate updates.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, "Iovance delivered approximately 30 percent quarterly revenue growth and achieved our 2025 guidance range in the first full calendar year of launch. Growth was driven by increasing demand for Amtagvi. After ongoing improvements in our operations and gross margin, we are well positioned for future profitability. Iovance is poised to create substantial value for patients and shareholders as we increase revenue while advancing our registrational trial in non-small cell lung cancer and best-in-class TIL pipeline in solid tumors."

Fourth Quarter and Full Year 2025 Financial Highlights
Topline Growth, Significant Margin Improvement, and Cost Optimization

Fourth quarter 2025 total product revenue of ~$87 million with strong growth of ~30% over the prior quarter, including:
U.S. Amtagvi revenue of ~$65 million.
Global Proleukin revenue of ~$22 million.
Fourth quarter 2025 gross margin from cost of sales was ~50%, reflecting increasing benefits from solid execution and cost optimization.
Full year 2025 total product revenue of ~$264 million achieved the guidance range of $250 million to $300 million in the first full year of launch, including:
U.S. Amtagvi revenue of ~$220 million.
Global Proleukin revenue of ~$44 million.
The cash position as of December 31, 2025 of ~$303 million1 is expected to fund operations into the third quarter of 2027.
Operational excellence initiatives, including internalization of all lifileucel manufacturing and optimization of research and development activities, are expected to drive significant additional improvements in operating expenses, cost of sales and gross margin in 2026 and 2027.
Amtagvi Commercial Launch
Strong U.S. Commercial Growth and Execution with Approvals Pending in New Global Markets

Best-in-class Amtagvi real-world response rates are increasing adoption and strengthening referral trends toward earlier treatment.
An oral presentation at the 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) reported:
An unprecedented overall objective response rate (ORR) of ~44%.
Higher ORR of 52% after two or fewer prior lines of therapy, highlighting the importance of early treatment.
A continuously growing and maturing network of U.S. authorized treatment centers (ATCs) expanded patient access in 2025, with further acceleration anticipated in 2026.
Academic ATCs are contributing to growth as new centers onboard and experienced centers treat more patients.
The first community ATCs began treating patients in late 2025 and are expected to drive additional demand in 2026.
A specialty pharmacy distribution channel was introduced as another option for ATCs to purchase Amtagvi.
Five-year analysis of the C-144-01 trial of Amtagvi demonstrated ~31% ORR, median duration of response (mDOR) of 36+ months, and ~20% five-year overall survival, highlighting the unprecedented long-term benefits of this first-in-class therapy.
Manufacturing turnaround improved to 32 days or less from inbound to return shipment to ATCs.
Global expansion of Amtagvi is underway in several markets outside the U.S.
Amtagvi was approved in Canada in August 2025.
Regulatory submissions are under review with potential approvals in the United Kingdom and Australia in the first half of 2026, and Switzerland in the first half of 2027.
Iovance is working with the European Medicines Agency (EMA) to resubmit a marketing authorization application (MAA) in 2026.
Lifileucel in Previously Treated Advanced NSCLC: IOV-LUN-202 Registrational Trial
Clinical and Regulatory Momentum Building Towards Potential 2H27 Launch

The U.S. FDA granted Fast Track Designation (FTD) for lifileucel for the treatment of adults with metastatic nonsquamous (NSQ) NSCLC that has progressed on or after chemo- and anti-PD-1 therapies and at least one line of FDA-approved targeted therapy, if indicated, for actionable tumor mutations excluding ALK, ROS1 and EGFR.
Positive interim data demonstrated a potential best-in-class profile in NSQ advanced NSCLC patients.
The ORR was 26% and mDOR was not reached at 25+ months of follow up following one-time lifileucel monotherapy.
Standard of care docetaxel has shown 12.8% ORR, 5.6 months mDOR, and 12.3 months overall survival, highlighting a significant unmet medical need.2
Anticipated milestones:
Present updated data at a major medical meeting in 2026.
Complete enrollment in 2026.
Support a supplemental Biologics License Application for U.S. accelerated approval with a potential launch in the second half of 2027.
Pipeline Updates
New Data Across Several Pipeline Programs Anticipated Throughout 2026

Iovance announced positive early data for one-time lifileucel treatment in patients with advanced undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS) who were refractory to at least one prior line of systemic therapy:
Among the first six evaluable patients, the confirmed RECIST v1.1 ORR was 50%.
Iovance plans to commence a single arm registrational trial in previously treated advanced UPS and DDLPS in the second quarter of 2026 and engage with the FDA on a path to expedited approval.
The Phase 3 TILVANCE-301 trial of lifileucel and pembrolizumab in frontline advanced melanoma made significant progress, with enrollment accelerating across a broad and expanding global footprint. The U.S. FDA previously granted FTD in frontline advanced melanoma for lifileucel in combination with pembrolizumab. The TILVANCE-301 trial is designed with FDA and EMA input to show contribution of components for lifileucel in combination with pembrolizumab compared to pembrolizumab alone.
Two of Iovance’s Phase 2 trials, IOV-END-201 and IOV-MEL-202, are investigating lifileucel in previously treated patients with advanced endometrial cancer and melanoma, respectively.
A Phase 1/2 trial is investigating IOV-4001, a PD-1 inactivated TIL therapy, in previously treated advanced melanoma and NSCLC.
A Phase 1/2 trial is investigating IOV-3001, a second-generation, modified IL-2 analog for use in the TIL treatment regimen.
An Investigational New Drug (IND) submission is planned in the first half of 2026 to begin clinical development of IOV-5001, a genetically engineered, inducible, and tethered interleukin-12 TIL therapy, in a Phase 1/2 basket trial.
Multiple investigator-sponsored clinical trials are exploring new solid tumor indications for Iovance TIL therapies and next generation approaches.
Webcast and Conference Call

Management will host a conference call and live audio webcast to discuss these results and provide a corporate update today at 8:30 a.m. ET. To listen to the live or archived audio webcast, please register at View Source The live and archived webcast can be accessed in the Investors section of the Company’s website, IR.Iovance.com, for one year.

(Press release, Iovance Biotherapeutics, FEB 24, 2026, View Source [SID1234662918])

On February 24, 2026 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, reported positive early data from a pilot clinical trial led by Memorial Sloan Kettering Cancer Center (MSKCC) and supported by Iovance of lifileucel in patients with advanced (metastatic or unresectable) undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS) who were refractory to at least one prior line of systemic therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Among the first six evaluable patients treated with lifileucel monotherapy, physician-assessed confirmed ORR by RECIST v1.1 was 50%. All evaluable patients had advanced disease, were refractory to prior therapy, and had significant disease burden, with a mean sum of diameters of 117 millimeters at baseline and a mean of more than two prior lines of therapy. Patients experienced deep responses that improved over time, consistent with lifileucel in melanoma, non-small-cell lung cancer, and other solid tumors. The safety profile was favorable and consistent with lifileucel therapy in other indications. Based on these results, Iovance plans to commence a single arm registrational trial in second-line advanced UPS and DDLPS in the second quarter of 2026 and will engage with the U.S. Food and Drug Administration (FDA) on an accelerated path to expedite approval. Iovance also plans to explore lifileucel in other high grade soft tissue sarcoma subtypes with high unmet need as part of its clinical development program.

UPS and DDLPS are high grade, aggressive soft tissue sarcomas associated with poor prognosis that impact more than 3,000 patients in the U.S. and more than 5,000 patients in Europe annually, including more than 3,500 patients with advanced disease.1-3 There is a high unmet medical need for new treatment options for second-line patients with recent clinical studies reporting ORRs of less than 5%, median progression-free survival (mPFS) of ~2-3 months, and median overall survival (mOS) of ~9-10 months.4-6

Lauren Baker Banks, MD, PhD, Sarcoma Medical Oncologist, MSKCC, stated, "In the first clinical trial of a TIL cell therapy in UPS and DDLPS, one-time treatment with lifileucel demonstrated compelling and unprecedented response rates with the potential to address a significant unmet need in patients who are refractory to frontline standard of care. Patients with UPS and DDLPS suffer from high disease burden, poor quality of life, and a lack of effective treatments, including no approved immunotherapy options. In the second-line setting, mPFS for many patients is only a few months with mOS less than a year. We look forward to presenting these results at a medical conference in 2026."

Dr. Brian Gastman, EVP Translational Medicine and Research at Iovance, stated, "The exciting clinical results show that lifileucel could offer a new, highly efficacious, and durable immunotherapy option in two aggressive forms of advanced sarcoma and further illustrate the promise of our TIL cell therapy platform to offer meaningful clinical benefit in multiple solid tumor cancers. Chemotherapy with extremely poor efficacy remains the second-line standard of care for these patients after progression on front-line chemotherapy. We look forward to bringing lifileucel to UPS and DDPLS patients as quickly as possible."

(Press release, Iovance Biotherapeutics, FEB 24, 2026, View Source [SID1234662917])

On February 24, 2026 Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, reported that management will be participating in the upcoming investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TD Cowen 46th Annual Health Care Conference
Date: Tuesday, March 3, 2026
Fireside Chat Time: 1:10 p.m. ET
Location: Boston, MA
Leerink Global Healthcare Conference
Date: Monday, March 9, 2026
Fireside Chat Time: 8:40 a.m. ET
Location: Miami, FL
Barclays 28th Annual Global Healthcare Conference
Date: Tuesday, March 10, 2026
Location: Miami, FL

The fireside chats on March 3 and March 9 will be webcast live. To join the webcasts, please visit the Events and Presentations page of the Investors & Media section on Intellia’s website at intelliatx.com. Replays of the webcasts will be available on this same page for approximately 90 days following the events.

(Press release, Intellia, FEB 24, 2026, View Source [SID1234662916])

On February 24, 2026 IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases, reported that William Ho, CEO and co-founder, will be presenting at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, at 9:50 am ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

William Ho will be giving a company presentation highlighting IN8bio’s latest achievements and upcoming milestones. The conference, to be held March 2-4, 2026, in Boston, will also include one-on-one investor meetings hosted by members of management.

A live webcast and replay link for the TD Cowen conference can be found here, and will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at View Source

(Press release, In8bio, FEB 24, 2026, View Source [SID1234662915])